<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517530</url>
  </required_header>
  <id_info>
    <org_study_id>BO20999</org_study_id>
    <secondary_id>2007-001103-37</secondary_id>
    <nct_id>NCT00517530</nct_id>
  </id_info>
  <brief_title>A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)</brief_title>
  <official_title>An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective for the phase I part of the study is to investigate the safety and
      tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy in
      participants with CD20+ (tumor-infiltrating lymphocytic) Malignant Disease, including B-cell
      chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). The primary objective
      for the phase II part of the study is to investigate the efficacy and safety of one dose of
      obinutuzumab in participants with relapsed/refractory CLL and NHL that is, in turn, either
      indolent (iNHL) or aggressive (aNHL).

      It is an open label dose escalating study in phase I and open label in phase II, but the two
      doses in iNHL &amp; aNHL are randomized (to high or low dose of the same open label treatment).
      CLL was not randomized as only one dose level was used.

      Participants with a response who might gain additional benefit from being treated again in
      the opinion of the investigator may be enrolled in a Retreatment Period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study</measure>
    <time_frame>Baseline to 28 days after the last infusion of obinutuzumab (up to 6 months)</time_frame>
    <description>Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Overall Response in Phase II of the Study</measure>
    <time_frame>by Cutoff Date: 31 March 2012 (within 3 years, 4 months)</time_frame>
    <description>Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study</measure>
    <time_frame>by Cutoff Date: 31 March 2012 (within 3 years, 4 months)</time_frame>
    <description>A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Response (PR) in Phase II of the Study</measure>
    <time_frame>by Cutoff Date: 31 March 2012 (within 3 years, 4 months)</time_frame>
    <description>A PR was defined as a &gt;=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by &gt;=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) in Phase II of the Study</measure>
    <time_frame>by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)</time_frame>
    <description>PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as &gt;= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A &gt;= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of &lt; 1.0 cm must increase by &gt;= 50% and to a size of 1.5×1.5 cm or &gt; 1.5 cm in the longest axis. (2) Appearance of any new lesion &gt; 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by Disease Type in Phase II of the Study</measure>
    <time_frame>by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)</time_frame>
    <description>Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as &gt;= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A &gt;= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of &lt; 1.0 cm must increase by &gt;= 50% and to a size of 1.5×1.5 cm or &gt; 1.5 cm in the longest axis. (2) Appearance of any new lesion &gt; 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Event-Free Survival (EFS) in Phase II of the Study</measure>
    <time_frame>by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)</time_frame>
    <description>EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study</measure>
    <time_frame>by the end of Phase II (within 3 years, 4 months)</time_frame>
    <description>B-cell depletion was defined in two ways: definition 1 - decrease below 5% baseline level and definition 2 - decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 - return to at least 50% of baseline level and definition 2 - return to at least 0.08 x 109/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Retreated Participants With Response</measure>
    <time_frame>by Cutoff Date: 25 November 2013 (within 4 years, 2 months)</time_frame>
    <description>Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants</measure>
    <time_frame>at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)</time_frame>
    <description>Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study</measure>
    <time_frame>Day 1 of Cycle 1</time_frame>
    <description>Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Obinutuzumab in CLL Patients</measure>
    <time_frame>at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)</time_frame>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase I, NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400/400 mg - Phase II, iNHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1600/800 mg - Phase II, iNHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400/400 mg - Phase II, aNHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1600/800 mg - Phase II, aNHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000/1000 mg - Phase II, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retreated Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.</description>
    <arm_group_label>Phase I, NHL</arm_group_label>
    <arm_group_label>Phase I, CLL</arm_group_label>
    <arm_group_label>400/400 mg - Phase II, iNHL</arm_group_label>
    <arm_group_label>1600/800 mg - Phase II, iNHL</arm_group_label>
    <arm_group_label>400/400 mg - Phase II, aNHL</arm_group_label>
    <arm_group_label>1600/800 mg - Phase II, aNHL</arm_group_label>
    <arm_group_label>1000/1000 mg - Phase II, CLL</arm_group_label>
    <arm_group_label>Retreated Participants</arm_group_label>
    <other_name>RO5072759</other_name>
    <other_name>GA101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;=18 years of age;

          -  Phase 1 only: CD20+ malignant disease (B-cell lymphoma or B-CLL);

          -  Phase 2 only: relapsed or refractory indolent NHL, relapsed or refractory aggressive
             NHL or relapsed or refractory B-CLL

          -  Have a clinical indication for treatment as determined by the investigator

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Life expectancy &gt;12 weeks

        Exclusion Criteria:

          -  Prior use of any investigational antibody therapy or other agent within 6 months of
             study start;

          -  Prior use of any anti-cancer vaccine;

          -  Prior use of standard anti-lymphoma/leukemia therapy or radiation therapy within 4
             weeks of enrollment;

          -  Prior use of MabThera (rituximab) within 8 weeks of study entry;

          -  Prior administration of radioimmunotherapy 3 months prior to study entry;

          -  Central nervous system (CNS) lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2007</study_first_posted>
  <results_first_submitted>July 14, 2015</results_first_submitted>
  <results_first_submitted_qc>August 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2015</results_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Different patients were recruited into Phase I and Phase II, and analyzed separately based on their disease. In this adaptive trial design, some of those same patients were included in follow-up even if they did not complete treatment, and 13 who had initially responded to treatment but subsequently progressed were retreated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>50-2000 mg Phase I, NHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="P2">
          <title>400-2000 mg Phase I, CLL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="P3">
          <title>400/400 mg - Phase II, iNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="P4">
          <title>1600/800 mg - Phase II, iNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="P5">
          <title>400/400 mg - Phase II, aNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="P6">
          <title>1600/800 mg - Phase II, aNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="P7">
          <title>1000/1000 mg - Phase II, CLL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Retreated Population</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population: All enrolled participants who had received at least 1 dose of obinutuzumab.</population>
      <group_list>
        <group group_id="B1">
          <title>50-2000 mg Phase I, NHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="B2">
          <title>400-2000 mg Phase I, CLL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="B3">
          <title>400/400 mg - Phase II, iNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="B4">
          <title>1600/800 mg - Phase II, iNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="B5">
          <title>400/400 mg - Phase II, aNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="B6">
          <title>1600/800 mg - Phase II, aNHL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="B7">
          <title>1000/1000 mg - Phase II, CLL</title>
          <description>Obinutuzumab intravenous infusion</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="21"/>
            <count group_id="B6" value="19"/>
            <count group_id="B7" value="20"/>
            <count group_id="B8" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study</title>
        <description>Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.</description>
        <time_frame>Baseline to 28 days after the last infusion of obinutuzumab (up to 6 months)</time_frame>
        <population>Safety population: All enrolled participants in Phase I, who had received at least 1 dose of obinutuzumab by 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>50/100 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>100/200 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>200/400 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>400/800 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O5">
            <title>800/1200 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O6">
            <title>1200/2000 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O7">
            <title>1600/800 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O8">
            <title>400/800 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O9">
            <title>800/1200 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O10">
            <title>1200/2000 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O11">
            <title>1000/1000 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study</title>
          <description>Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.</description>
          <population>Safety population: All enrolled participants in Phase I, who had received at least 1 dose of obinutuzumab by 6 months.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Overall Response in Phase II of the Study</title>
        <description>Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
        <time_frame>by Cutoff Date: 31 March 2012 (within 3 years, 4 months)</time_frame>
        <population>Safety population: All enrolled participants in Phase II, who had received at least 1 dose of obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>400/400 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>1600/800 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>400/400 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>1600/800 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O5">
            <title>1000/1000 mg - Phase II, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Overall Response in Phase II of the Study</title>
          <description>Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
          <population>Safety population: All enrolled participants in Phase II, who had received at least 1 dose of obinutuzumab.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="36.8"/>
                    <measurement group_id="O5" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study</title>
        <description>A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.</description>
        <time_frame>by Cutoff Date: 31 March 2012 (within 3 years, 4 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>400/400 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>1600/800 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>400/400 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>1600/800 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O5">
            <title>1000/1000 mg - Phase II, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study</title>
          <description>A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="9.5"/>
                    <measurement group_id="O4" value="15.8"/>
                    <measurement group_id="O5" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRu</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="NA">CRu was measured only in participants with NHL</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">CRi was measured only in participants with CLL</measurement>
                    <measurement group_id="O2" value="NA">CRi was measured only in participants with CLL</measurement>
                    <measurement group_id="O3" value="NA">CRi was measured only in participants with CLL</measurement>
                    <measurement group_id="O4" value="NA">CRi was measured only in participants with CLL</measurement>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Partial Response (PR) in Phase II of the Study</title>
        <description>A PR was defined as a &gt;=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by &gt;=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.</description>
        <time_frame>by Cutoff Date: 31 March 2012 (within 3 years, 4 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>400/400 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>1600/800 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>400/400 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>1600/800 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O5">
            <title>1000/1000 mg - Phase II, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Partial Response (PR) in Phase II of the Study</title>
          <description>A PR was defined as a &gt;=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by &gt;=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="40.9"/>
                    <measurement group_id="O3" value="9.5"/>
                    <measurement group_id="O4" value="21.1"/>
                    <measurement group_id="O5" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) in Phase II of the Study</title>
        <description>PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin’s lymphoma participants, PD was defined as &gt;= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A &gt;= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of &lt; 1.0 cm must increase by &gt;= 50% and to a size of 1.5×1.5 cm or &gt; 1.5 cm in the longest axis. (2) Appearance of any new lesion &gt; 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation.</description>
        <time_frame>by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)</time_frame>
        <population>Safety population: All enrolled participants in Phase II, who had received at least 1 dose of obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>400/400 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>1600/800 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>400/400 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>1600/800 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O5">
            <title>1000/1000 mg - Phase II, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) in Phase II of the Study</title>
          <description>PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin’s lymphoma participants, PD was defined as &gt;= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A &gt;= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of &lt; 1.0 cm must increase by &gt;= 50% and to a size of 1.5×1.5 cm or &gt; 1.5 cm in the longest axis. (2) Appearance of any new lesion &gt; 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation.</description>
          <population>Safety population: All enrolled participants in Phase II, who had received at least 1 dose of obinutuzumab.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182" lower_limit="106" upper_limit="526"/>
                    <measurement group_id="O2" value="361" lower_limit="343" upper_limit="678"/>
                    <measurement group_id="O3" value="78" lower_limit="42" upper_limit="260"/>
                    <measurement group_id="O4" value="83" lower_limit="43" upper_limit="339"/>
                    <measurement group_id="O5" value="324" lower_limit="217" upper_limit="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response by Disease Type in Phase II of the Study</title>
        <description>Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin’s lymphoma participants, PD was defined as &gt;= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A &gt;= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of &lt; 1.0 cm must increase by &gt;= 50% and to a size of 1.5×1.5 cm or &gt; 1.5 cm in the longest axis. (2) Appearance of any new lesion &gt; 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.</description>
        <time_frame>by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)</time_frame>
        <population>Safety population: All enrolled participants in Phase II, who had received at least 1 dose of obinutuzumab. Data reported for each disease cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion at 400/400 mg and 1600/800 mg</description>
          </group>
          <group group_id="O2">
            <title>Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion at 400/400 mg and 1600/800 mg</description>
          </group>
          <group group_id="O3">
            <title>Phase II, CLL</title>
            <description>Obinutuzumab intravenous infusion at 1000/1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response by Disease Type in Phase II of the Study</title>
          <description>Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin’s lymphoma participants, PD was defined as &gt;= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A &gt;= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of &lt; 1.0 cm must increase by &gt;= 50% and to a size of 1.5×1.5 cm or &gt; 1.5 cm in the longest axis. (2) Appearance of any new lesion &gt; 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.</description>
          <population>Safety population: All enrolled participants in Phase II, who had received at least 1 dose of obinutuzumab. Data reported for each disease cohort.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523" lower_limit="23" upper_limit="952"/>
                    <measurement group_id="O2" value="298" lower_limit="95" upper_limit="929"/>
                    <measurement group_id="O3" value="272.5" lower_limit="23" upper_limit="794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Event-Free Survival (EFS) in Phase II of the Study</title>
        <description>EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.</description>
        <time_frame>by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>400/400 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>1600/800 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>400/400 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>1600/800 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O5">
            <title>1000/1000 mg - Phase II, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Event-Free Survival (EFS) in Phase II of the Study</title>
          <description>EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study</title>
        <description>B-cell depletion was defined in two ways: definition 1 – decrease below 5% baseline level and definition 2 – decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 – return to at least 50% of baseline level and definition 2 – return to at least 0.08 x 109/L.</description>
        <time_frame>by the end of Phase II (within 3 years, 4 months)</time_frame>
        <population>Participants analyzed include those with B-cell depletion at the end of treatment (N), with assessments (n) at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>400/400 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>1600/800 mg - Phase II, iNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>400/400 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>1600/800 mg - Phase II, aNHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O5">
            <title>1000/1000 mg - Phase II, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study</title>
          <description>B-cell depletion was defined in two ways: definition 1 – decrease below 5% baseline level and definition 2 – decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 – return to at least 50% of baseline level and definition 2 – return to at least 0.08 x 109/L.</description>
          <population>Participants analyzed include those with B-cell depletion at the end of treatment (N), with assessments (n) at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>within 6 months (n=11,19,11,12,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 9 months (n=8,17,6,5,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 12 months (n=5,16,4,5,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 18 months (n=4,13,3,3,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 24 months (n=3,10,2,3,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 24 months (n=3,4,1,2,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Retreated Participants With Response</title>
        <description>Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.</description>
        <time_frame>by Cutoff Date: 25 November 2013 (within 4 years, 2 months)</time_frame>
        <population>Retreated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Retreated Participants</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Retreated Participants With Response</title>
          <description>Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.</description>
          <population>Retreated participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Best overall response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants</title>
        <description>Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses.</description>
        <time_frame>at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)</time_frame>
        <population>Pharmacokinetics (PK)- evaluable population at the given dose (e.g., 3 or more participants at any of the given time points). Other doses did not have a PK-evaluable population, so were not included in the table of results. Due to the limited sampling schedule derived PK parameters could not be accurately obtained during Cycle 1 and Cycle 8.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>800 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>1200 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>2000 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants</title>
          <description>Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses.</description>
          <population>Pharmacokinetics (PK)- evaluable population at the given dose (e.g., 3 or more participants at any of the given time points). Other doses did not have a PK-evaluable population, so were not included in the table of results. Due to the limited sampling schedule derived PK parameters could not be accurately obtained during Cycle 1 and Cycle 8.</population>
          <units>µm/ml*day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1 (n=4,6,6,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="27.1"/>
                    <measurement group_id="O2" value="234" spread="63.1"/>
                    <measurement group_id="O3" value="307" spread="30.6"/>
                    <measurement group_id="O4" value="NA">n=0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 8 (n=0,4,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">n=0</measurement>
                    <measurement group_id="O2" value="367" spread="24.2"/>
                    <measurement group_id="O3" value="449" spread="26.4"/>
                    <measurement group_id="O4" value="714" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 (n=0,5,5,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">n=0</measurement>
                    <measurement group_id="O2" value="698" spread="65.4"/>
                    <measurement group_id="O3" value="1070" spread="62.6"/>
                    <measurement group_id="O4" value="1380" spread="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study</title>
        <description>Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab.</description>
        <time_frame>Day 1 of Cycle 1</time_frame>
        <population>Pharmacokinetics (PK)- evaluable population at the given dose (e.g., 3 or more participants). Other doses did not have a PK-evaluable population, so were not included in the table of results. Due to the limited sampling schedule derived PK parameters could not be accurately obtained during Cycle 1 and Cycle 8.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>800 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>1200 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>2000 mg - Phase I, NHL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study</title>
          <description>Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab.</description>
          <population>Pharmacokinetics (PK)- evaluable population at the given dose (e.g., 3 or more participants). Other doses did not have a PK-evaluable population, so were not included in the table of results. Due to the limited sampling schedule derived PK parameters could not be accurately obtained during Cycle 1 and Cycle 8.</population>
          <units>µm/ml*day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459" spread="64.7"/>
                    <measurement group_id="O2" value="993" spread="30.5"/>
                    <measurement group_id="O3" value="1057" spread="60.5"/>
                    <measurement group_id="O4" value="146" spread="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Plasma Concentration (Cmax) of Obinutuzumab in CLL Patients</title>
        <time_frame>at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>400 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>800 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>1200 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
          <group group_id="O4">
            <title>2000 mg - Phase I, CLL</title>
            <description>Obinutuzumab intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Obinutuzumab in CLL Patients</title>
          <units>micrograms/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1 (n=3,3,3,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" spread="34.1"/>
                    <measurement group_id="O2" value="210" spread="74.0"/>
                    <measurement group_id="O3" value="307" spread="21.4"/>
                    <measurement group_id="O4" value="NA">n=0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 8 (n=0,0,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">n=0</measurement>
                    <measurement group_id="O2" value="NA">n=0</measurement>
                    <measurement group_id="O3" value="437" spread="11.8"/>
                    <measurement group_id="O4" value="735" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 (n=3,3,3,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485" spread="48.1"/>
                    <measurement group_id="O2" value="573" spread="73.2"/>
                    <measurement group_id="O3" value="741" spread="32.8"/>
                    <measurement group_id="O4" value="1730" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through final cut off in November 2013</time_frame>
      <desc>For frequency counts by preferred term, multiple occurrences of the same adverse event (AE) in an individual are counted only once.</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Population</title>
          <description>Safety-Evaluable Participants</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Cardiorespiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tooth avulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tumour lysis sydrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pharmacodynamic results were limited because number of participants was inversely proportional to length of follow-up. In other words, there were fewer participants still in the trial as the follow-up period became longer.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

